Condition: Stroke, Acute Ischemic · Blood-Brain Barrier · Sponsor: yilong Wang
A pilot study confirmed the feasibility and safety of neuroprotectant Y-3 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional scores compared to conventional treatment. The aim of this trial is to further investigate the efficacy and safety of ICO injection of Y-3 compared to intravenous injection in patients with acute large hemispheric infarction(LHI) who has contraindications of reperfusion therapy or have got poor reperfusion therapy outcomes.
This description comes directly from the study's public registry record.
Yilong Wang, PhD+MD · 18842627325/13261655100 · yilong528@gmail.com
Always discuss trial participation with your own doctor first.
| The first affiliated hospital of Wannan Medical College | Wuhu, Anhui, China | Recruiting |
| Beijing Tiantan Hospital | Beijing, Beijing Municipality, China | Recruiting |
| North China University of Science and Technology Affiliated Hospital | Tangshan, Heibei, China | Recruiting |
| Tangshan Municipal Worker's Hospital | Tangshan, Heibei, China | Withdrawn |
| Shaanxi Provincial People's Hospital | Xi'an, Shaanxi, China | Recruiting |
| Tianjin Huanhu hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06374667